Y-33075

• Description:

  Y-33075 is a selective ROCK inhibitor derived from Y-27632, and is more potent than Y-27632, with an IC50 of 3.6 nM.

• Product Name Alternative:

  Y-39983 (free base)

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H320

• Target:

  ROCK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; Cytoskeleton; Stem Cell/Wnt; TGF-beta/Smad

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Y-33075.html

• Concentration:

  10mM

• Purity:

  98.44

• Solubility:

  DMSO : 50 mg/mL (ultrasonic; warming) |H2O : < 0.1 mg/mL

• Smiles:

  O=C(NC1=C2C(NC=C2)=NC=C1)C3=CC=C(C=C3)[C@H](N)C

• Molecular Formula:

  C16H16N4O

• Molecular Weight:

  280.33

• Precautions:

  H315, H319, H320

• References & Citations:

  [1]Hideki Tokushige, et al. Effects of Topical Administration of Y-39983, a Selective Rho-Associated Protein Kinase Inhibitor, on Ocular Tissues in Rabbits and Monkeys Invest. Ophthalmol. Vis. Sci. July 2007 vol. 48no. 7 3216-3222|[2]Tokushige H, et al. Effects of Y-39983, a selective Rho-associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats. Curr Eye Res. 2011 Oct;36 (10) :964-70.|[3]Watabe H, et al. Effects of Rho-associated protein kinase inhibitors Y-27632 and Y-39983 on isolated rabbit ciliary arteries.Jpn J Ophthalmol. 2011 Jul;55 (4) :411-7. Epub 2011 Jun 11.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• Isoform:

  ROCK

• Citation 01:

  Acta Neuropathol Commun. 2024 Sep 14;12 (1) :150.|bioRxiv. 2025 June 03.|Cell Death Dis. 2024 Dec 26;15 (12) :932.|Cells. 2024 Nov 18;13 (22) :1907.|J Cell Physiol. 2021 Dec;236 (12) :8226-8238.|Patent. US20170349879A1.|PLoS One. 2023 Jan 31;18 (1) :e0270288.|Stem Cell Rep. 2020 Jan 14;14 (1) :49-59.|Adv Sci (Weinh) . 2022 May;9 (13) :e2104682.|Cell. 2018 Jul 26;174 (3) :636-648.e18.|Harvard Medical School LINCS LIBRARY|J Adv Res. 2024 Sep:63:117-128.|Nat Commun. 2020 Jan 3;11 (1) :88.|Neurotox Res. 2013 Apr;23 (3) :238-48.|Science. 2017 Dec 1;358 (6367) :eaan4368.

• CAS Number:

  [199433-58-4]